Iranex aims to grow by 40% in five years

By increasing his shareholding to almost 76%, Iranex Group CEO and MD Stéphane Dondain puts an end to the rumors of transfer and reaffirms the Group’s independence and his confidence in its future.

The Iranex group, which is composed of CNI, Bioserae Laboratories, Starlight Products, NutriProcess, and Afritec, provides natural ingredients for the food and nutraceuticals industries. The Group has an annual turnover of approximately 70 million Euros ($95.6 million), 90% of which is in export sales. Dondain said in the next five years, the Group aims to strengthen the synergies between its companies and to reach a turnover of 100 million Euros by 2015. This goal of 40% growth over five years will be achieved by combining organic growth (8% on average in recent years) and external expansion operations.